New Glaucoma Treatments in 2026: What Patients Should Know About Longer-Lasting Eye Pressure Control
Below we explain how these new treatments work, who might benefit, and how they compare to traditional drops. We focus on the options most talked...
Deep research and expert guides on maintaining your visual health.
Below we explain how these new treatments work, who might benefit, and how they compare to traditional drops. We focus on the options most talked...
Blind spots often develop gradually without symptoms. Start a free trial and take a quick visual field test to spot changes early.
Find Out NowiDose TR is a tiny implantable device designed to deliver the glaucoma medicine travoprost directly inside the eye over an extended period. A doctor places it in a small procedure so the device sits where the drug can reach the tissues that control fluid pressure. Instead of applying eye drops every day, the device releases medication slowly and continuously, aiming to keep eye pressure stable. This steadier dosing can reduce the burden of daily treatment and help people who have trouble using drops correctly. Some versions of the device are designed so a clinician can remove or replace them if needed, giving flexibility in long-term management. As with any implant, there are risks such as procedure-related infection, device movement, or local tissue reactions that doctors watch for. Not every patient is a candidate, and the choice between an implanted system and traditional drops depends on eye anatomy, disease severity, and personal preference. iDose TR matters because it represents a shift toward treating chronic eye conditions with steady, low-maintenance approaches that may improve outcomes. Patients considering it should discuss expected benefits, possible complications, and follow-up care with their eye specialist before deciding so they understand how it fits into their plan to keep vision healthy.